Kura Oncology will host a virtual investor event on December 9 to discuss ziftomenib's clinical trial updates.
Quiver AI Summary
Kura Oncology, Inc. announced a virtual investor event set for December 9, 2024, at 8:00 a.m. ET to discuss its KOMET-007 clinical trial for the oral menin inhibitor, ziftomenib, following new data presented at the ASH Annual Meeting. The event will feature the management team and trial investigators, and interested parties can join via phone or webcast. Kura's pipelines focus on precision medicines for cancer, with ziftomenib recognized by the FDA as a Breakthrough Therapy for a specific type of leukemia. The company has also entered a global collaboration with Kyowa Kirin for ziftomenib's development and is planning a New Drug Application submission in 2025. Other drug candidates are in various stages of clinical trials for different cancers.
Potential Positives
- The announcement of a virtual investor event demonstrates Kura Oncology's commitment to transparency and engagement with stakeholders regarding its clinical developments.
- Ziftomenib has received Breakthrough Therapy Designation from the FDA, highlighting its potential significance in the treatment of relapsed/refractory NPM1-mutant acute myeloid leukemia.
- The global strategic collaboration agreement with Kyowa Kirin for ziftomenib indicates strong industry partnerships, potentially enhancing development and commercialization efforts.
- Completion of enrollment in the Phase 2 registration-directed trial of ziftomenib positions the company well for a New Drug Application submission anticipated in 2025, suggesting progress in their drug development pipeline.
Potential Negatives
- The announcement of a virtual investor event may indicate a lack of in-person engagement opportunities, which can be perceived as a weakness in corporate transparency and stakeholder communication.
- The timing of the event, shortly after the ASH Annual Meeting, could suggest that the company is attempting to manage expectations regarding the reception and implications of their clinical data.
- While Kura announced a strategic collaboration with Kyowa Kirin, the partnership might raise concerns regarding reliance on external companies for development and commercialization efforts, potentially impacting the company's control over its pipeline.
FAQ
What is the date and time of Kura Oncology's virtual investor event?
Kura Oncology's virtual investor event is scheduled for December 9, 2024, at 8:00 a.m. ET / 5:00 a.m. PT.
How can I access the live webcast for the KOMET-007 trial discussion?
The live webcast can be accessed through Kura Oncology's website and in the Investors section shortly before the event.
What is ziftomenib, and what is its significance?
Ziftomenib is an oral, selective menin inhibitor and the first investigational therapy with Breakthrough Therapy Designation for relapsed/refractory NPM1-mutant AML.
What clinical trials is Kura conducting with ziftomenib?
Kura is conducting trials to evaluate ziftomenib in various settings, including combination therapies for newly diagnosed and relapsed/refractory AML.
Who can I contact for investor relations at Kura Oncology?
You can contact Pete De Spain, Executive Vice President, Investor Relations, at (858) 500-8833 or pete@kuraoncology.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KURA Insider Trading Activity
$KURA insiders have traded $KURA stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here's a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
- KATHLEEN FORD (Chief Operating Officer) sold 526 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KURA Hedge Fund Activity
We have seen 81 institutional investors add shares of $KURA stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. removed 1,819,884 shares (-100.0%) from their portfolio in Q3 2024
- DEEP TRACK CAPITAL, LP added 1,578,749 shares (+410.3%) to their portfolio in Q3 2024
- BVF INC/IL removed 710,276 shares (-17.4%) from their portfolio in Q3 2024
- ASSENAGON ASSET MANAGEMENT S.A. removed 679,514 shares (-39.2%) from their portfolio in Q3 2024
- SUVRETTA CAPITAL MANAGEMENT, LLC added 583,155 shares (+8.2%) to their portfolio in Q3 2024
- SOFINNOVA INVESTMENTS, INC. removed 528,359 shares (-64.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 505,712 shares (+149.0%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company's oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66
th
American Society of Hematology (ASH) Annual Meeting in San Diego.
The virtual event will feature members of the management team along with investigators from the KOMET-007 trial. The live call may be accessed by dialing (800) 715-9871 for domestic callers and (646) 307-1963 for international callers and entering the conference ID: 4326549. A live webcast will be available
here
and in the Investors section of Kura's website, with an archived replay available shortly after the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed and the companies anticipate submission of a New Drug Application in 2025. Kura is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at
and follow us on
X
and
LinkedIn
.
Kura Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
